Stoneridge Investment Partners LLC Decreases Stock Holdings in Becton, Dickinson and Company $BDX

Stoneridge Investment Partners LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 87.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,323 shares of the medical instruments supplier’s stock after selling 23,014 shares during the period. Stoneridge Investment Partners LLC’s holdings in Becton, Dickinson and Company were worth $622,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in BDX. Bill Few Associates Inc. grew its position in Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 55 shares in the last quarter. Gilbert & Cook Inc. raised its position in Becton, Dickinson and Company by 2.0% during the second quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after purchasing an additional 56 shares during the period. Mendel Money Management lifted its stake in shares of Becton, Dickinson and Company by 2.6% in the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after purchasing an additional 58 shares during the last quarter. Focus Financial Network Inc. boosted its holdings in shares of Becton, Dickinson and Company by 2.2% in the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after purchasing an additional 58 shares during the period. Finally, CX Institutional increased its position in shares of Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock valued at $324,000 after purchasing an additional 60 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Down 2.0%

BDX stock opened at $201.84 on Friday. The company has a market capitalization of $57.51 billion, a PE ratio of 34.62, a P/E/G ratio of 2.23 and a beta of 0.23. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The firm’s 50-day moving average is $197.40 and its 200 day moving average is $190.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.92 by $0.04. The company had revenue of $5.89 billion during the quarter, compared to analysts’ expectations of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the company earned $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Analysts Set New Price Targets

A number of analysts recently issued reports on BDX shares. Piper Sandler lowered their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Jefferies Financial Group raised their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $207.64.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,662 shares of company stock worth $535,246 over the last 90 days. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.